Abstract
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the flow cytometric data in Fig.3A and western blotting data featured in Figs.3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors. Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 45:1537‑1546, 2014; DOI: 10.3892/ijo.2014.2577].
Highlights
Following the publication of this paper, it was drawn to the Editors’ attention by a concerned reader that the flow cytometric data in Fig. 3A and western blotting data featured in Figs. 3C and 7 were strikingly similar to data appearing in different form in other articles that shared some of the same authors
Owing to the fact that the contentious data in the above article were already under consideration for publication, or had already been published, elsewhere prior to its submission to International Journal of Oncology, the Editor has decided that this paper should be retracted from the Journal
The Editor apologizes to the readership for any inconvenience caused
Summary
MiR‐222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.